Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Mesoblast Ltd

Healthcare US MESO

15.74USD
0.31(2.01%)

Last update at 2026-03-10T20:02:00Z

Day Range

15.4516.03
LowHigh

52 Week Range

5.7822.00
LowHigh

Fundamentals

  • Previous Close 15.43
  • Market Cap1488.42M
  • Volume257592
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-49.42500M
  • Revenue TTM5.67M
  • Revenue Per Share TTM0.05
  • Gross Profit TTM -20.99039M
  • Diluted EPS TTM-0.96

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -82.10100M -91.58600M -99.63000M -87.35500M -98.75400M
Minority interest - - - - -
Net income -81.88900M -91.34700M -98.81100M -77.94000M -89.79900M
Selling general administrative 25.37M 27.21M 30.87M 25.61M 21.62M
Selling and marketing expenses 27.73M 30.76M 32.72M 25.31M 15.36M
Gross profit 7.50M 10.21M 7.46M 32.16M 16.72M
Reconciled depreciation 4.11M 4.38M 4.26M 3.67M 2.14M
Ebit -69.13600M -80.95300M -111.86700M -79.07200M -83.30100M
Ebitda -65.02900M -76.57300M -107.60300M -75.40500M -81.16200M
Depreciation and amortization 4.11M 4.38M 4.26M 3.67M 2.14M
Non operating income net other - - - - -
Operating income -69.13600M -80.95300M -111.86700M -79.07200M -83.30100M
Other operating expenses 76.79M 90.78M 115.06M 107.56M 97.88M
Interest expense 19.44M 16.91M 10.71M 13.33M 11.33M
Tax provision -0.21200M -0.23900M -0.81900M -9.41500M -8.95500M
Interest income 0.83M 0.00300M 0.02M 0.54M 0.72M
Net interest income -19.29100M -17.28500M -10.71400M -14.71600M -11.70400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.21200M -0.23900M -0.81900M -9.41500M -8.95500M
Total revenue 7.50M 10.21M 7.46M 32.16M 16.72M
Total operating expenses 76.79M 90.78M 115.06M 107.56M 97.88M
Cost of revenue - - - - 15.36M
Total other income expense net 6.48M -10.63300M 12.24M -8.28300M -15.45300M
Discontinued operations - - - - -
Net income from continuing ops -81.88900M -91.34700M -98.81100M -77.94000M -89.79900M
Net income applicable to common shares -81.88900M -91.34700M -98.81100M -77.94000M -89.79900M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 669.15M 669.41M 662.14M 744.72M 733.60M
Intangible assets 441.28M 442.73M 444.20M 446.09M 447.15M
Earning assets - - - - -
Other current assets 2.55M 1.42M 5.40M 11.35M 7.22M
Total liab 188.80M 167.58M 165.10M 163.32M 184.28M
Total stockholder equity 480.36M 501.84M 497.04M 581.40M 549.33M
Deferred long term liab - - - - -
Other current liab 49.69M 5.43M 20.09M 18.71M 29.20M
Common stock 1310.81M 1249.12M 1165.31M 1163.15M 1051.45M
Capital stock 1310.81M 1249.12M 1165.31M 1163.15M 1051.45M
Retained earnings -908.76100M -820.80500M -738.91600M -647.56900M -548.75800M
Other liab - 19.11M 15.02M 19.52M 30.79M
Good will 134.45M 134.45M 134.45M 134.45M 134.45M
Other assets - 2.33M 1.93M 1.72M 3.31M
Cash 62.56M 70.92M 60.03M 136.88M 129.33M
Cash and equivalents - - - - -
Total current liabilities 73.24M 41.98M 51.37M 94.27M 90.14M
Current deferred revenue - 6.40M - - 23.45M
Net debt 56.36M 45.58M 46.87M -31.38600M -30.01400M
Short term debt 16.49M 10.01M 8.20M 55.97M 35.97M
Short long term debt 13.86M 5.95M 5.02M 53.20M 32.45M
Short long term debt total 118.92M 116.50M 106.91M 105.50M 99.31M
Other stockholder equity - 73.52M 1235.96M 1228.97M 1098.08M
Property plant equipment - 6.49M 9.96M 12.14M 10.27M
Total current assets 86.46M 81.66M 69.84M 148.23M 136.55M
Long term investments 1.01M 1.76M 1.76M 2.08M 1.87M
Net tangible assets - -75.34500M -81.60800M 0.85M -32.27500M
Short term investments - - - - -
Net receivables 20.95M 7.00M 4.40M 4.84M 1.57M
Long term debt 100.48M 102.81M 91.62M 41.05M 57.02M
Inventory - - - -4.84200M -1.57400M
Accounts payable 7.07M 20.14M 23.08M 19.60M 24.97M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 78.30M 73.52M 70.65M 65.81M 46.63M
Additional paid in capital - - - - -
Common stock total equity - - - 1163.15M 1051.45M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.10M 0.48M 1.93M 1.72M 3.31M
Deferred long term asset charges - - - - -
Non current assets total 582.69M 587.76M 592.30M 596.49M 597.05M
Capital lease obligations 4.58M 7.73M 10.27M 11.25M 9.84M
Long term debt total - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.19400M -0.23200M -1.64700M -3.27300M -1.00000M
Change to liabilities -0.39800M 4.78M -5.06100M 14.01M -2.24300M
Total cashflows from investing activities -0.19400M -0.23200M -1.64700M -3.27300M -1.00000M
Net borrowings -2.65600M -6.32700M -2.93100M -1.62500M 43.57M
Total cash from financing activities 74.50M -9.87000M 114.47M 137.04M 71.61M
Change to operating activities 0.43M -0.04800M -1.61800M -1.60700M 17.71M
Net income -81.88900M -91.34700M -98.81100M -77.94000M -89.79900M
Change in cash 10.87M -76.43400M 7.55M 78.90M 12.66M
Begin period cash flow 60.45M 136.88M 129.33M 50.43M 37.76M
End period cash flow 71.32M 60.45M 136.88M 129.33M 50.43M
Total cash from operating activities -63.26900M -65.78200M -106.68100M -56.36500M -57.79000M
Issuance of capital stock 88.64M 0.21M 106.27M 144.95M 30.26M
Depreciation 4.11M 4.38M 4.26M 3.67M 2.14M
Other cashflows from investing activities 0.12M 0.12M 0.12M 0.12M -0.72100M
Dividends paid 0.00000M 0.00000M - 0.00000M -
Change to inventory - - - - -
Change to account receivables -0.11800M 0.14M -1.73900M 0.89M 4.97M
Sale purchase of stock - - - - 30.26M
Other cashflows from financing activities -11.47700M 48.17M 11.13M -5.76500M 41.35M
Change to netincome 16.98M 16.32M -3.71600M 4.62M 9.43M
Capital expenditures 0.31M 0.23M 1.65M 2.25M 0.28M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.47200M 4.87M -8.41800M 13.29M 20.44M
Stock based compensation 3.65M 5.54M 12.51M 7.52M 4.37M
Other non cash items 13.54M 11.02M -15.40700M 6.51M 14.02M
Free cash flow -63.58300M -66.01400M -108.32800M -58.61100M -58.06900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
MESO
Mesoblast Ltd		 0.31 2.01% 15.74 - 454.55 262.51 3.23 137.12 -6.5491
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Mesoblast Ltd

55 Collins Street, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director 1957
Dr. Eric A. Rose M.D. Chief Medical Officer & Exec. Director 1951
Mr. Andrew Chaponnel B.Com. Interim Chief Fin. Officer NA
Ms. Dagmar Rosa-Bjorkeson M.B.A., M.S. Chief Operating Officer 1964
Mr. Peter T. Howard B.Sc., L.L.B., BSc, LLB (Hons) Gen. Counsel & Corp. Exec. 1968
Mr. Roger D. Brown BA Head of Spinal Orthopedic Disorders NA
Mr. Michael Schuster M.B.A., MS, BSc, MBA Head of Pharma Partnering 1977
Ms. Geraldine Storton B.Sc., M.B.A., Bsc, MMS, MBA Head of Regulatory Affairs & Quality Management NA
Mr. Justin Horst B.S. Head of Manufacturing NA
Ms. Niva Sivakumar B.Com., L.L.B. Joint Company Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.